Anti-Tat immunity defines CD4

Antiretroviral Therapy, Highly Active B-Lymphocytes / immunology Biomarkers CD4 Lymphocyte Count CD4-Positive T-Lymphocytes / immunology CD8-Positive T-Lymphocytes / immunology HIV Antibodies / immunology HIV Infections / drug therapy HIV-1 / immunology Host-Pathogen Interactions / immunology Humans Immunophenotyping Lymphocyte Activation Viral Load tat Gene Products, Human Immunodeficiency Virus / immunology

Anti-Tat antibodies Anti-Tat cellular immunity CD4+ T cells HIV immune activation HIV reservoirs HIV residual viremia HIV-1 Tat Perspective for clinical implications

Journal

EBioMedicine

ISSN: 2352-3964

Titre abrégé: EBioMedicine

Pays: Netherlands

ID NLM: 101647039

Informations de publication

Date de publication:
Apr 2021

Historique:

received: 14 01 2021

revised: 10 03 2021

accepted: 11 03 2021

pubmed: 12 4 2021

medline: 30 11 2021

entrez: 11 4 2021

Statut: ppublish

Résumé

Low-level HIV viremia originating from virus reactivation in HIV reservoirs is often present in cART treated individuals and represents a persisting source of immune stimulation associated with sub-optimal recovery of CD4 Volunteers enrolled in a 3-year longitudinal observational study were stratified by residual viremia, Tat serostatus and frequency of anti-Tat cellular immune responses. The impact of anti-Tat immunity on low-level viremia, persistent immune activation and CD4 Anti-Tat immunity is significantly associated with higher nadir CD4 Therapeutic approaches aiming at reinforcing anti-Tat immunity should be investigated to improve immune reconstitution in people living with HIV on long-term cART. ISS OBS T-002 ClinicalTrials.gov identifier: NCT01024556 FUNDING: Italian Ministry of Health, special project on the Development of a vaccine against HIV based on the Tat protein and Ricerca Corrente 2019/2020.

Sections du résumé

BACKGROUND BACKGROUND

METHODS METHODS

Volunteers enrolled in a 3-year longitudinal observational study were stratified by residual viremia, Tat serostatus and frequency of anti-Tat cellular immune responses. The impact of anti-Tat immunity on low-level viremia, persistent immune activation and CD4

FINDINGS RESULTS

Anti-Tat immunity is significantly associated with higher nadir CD4

INTERPRETATION CONCLUSIONS

Therapeutic approaches aiming at reinforcing anti-Tat immunity should be investigated to improve immune reconstitution in people living with HIV on long-term cART.

TRIAL REGISTRATION BACKGROUND

ISS OBS T-002 ClinicalTrials.gov identifier: NCT01024556 FUNDING: Italian Ministry of Health, special project on the Development of a vaccine against HIV based on the Tat protein and Ricerca Corrente 2019/2020.

Identifiants

DOI: 10.1016/j.ebiom.2021.103306 PMID: 33839064 PMC: PMC8105504

pubmed: 33839064

pii: S2352-3964(21)00099-2

doi: 10.1016/j.ebiom.2021.103306

pmc: PMC8105504

pii:

doi:

Substances chimiques

Biomarkers 0

HIV Antibodies 0

tat Gene Products, Human Immunodeficiency Virus 0

Banques de données

ClinicalTrials.gov

['NCT01024556']

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

Pagination

103306

Commentaires et corrections

Type : CommentIn

Informations de copyright

Déclaration de conflit d'intérêts

Declaration of Competing Interest M. Di Pietro reports grants received from the Azienda Sanitaria of Florence during the conduct of the study. The other authors declares no conflict of interest.

Références

J Virol. 1993 Jan;67(1):277-87

pubmed: 8416373

Proc Natl Acad Sci U S A. 2000 Oct 10;97(21):11466-71

pubmed: 11027346

Clin Infect Dis. 2007 Feb 1;44(3):441-6

pubmed: 17205456

Retrovirology. 2016 Jun 09;13(1):34

pubmed: 27277839

J Virol. 1998 Nov;72(11):8952-60

pubmed: 9765440

AIDS. 2014 Sep 24;28(15):2189-200

pubmed: 25313583

Clin Infect Dis. 2009 Mar 15;48(6):787-94

pubmed: 19193107

J Infect Dis. 2003 Oct 15;188(8):1171-80

pubmed: 14551888

Retrovirology. 2015 Apr 29;12:33

pubmed: 25924841

Antivir Ther. 2007;12(6):971-5

pubmed: 17926652

J Virol. 1992 Dec;66(12):7159-67

pubmed: 1279199

Immunity. 2013 Oct 17;39(4):633-45

pubmed: 24138880

PLoS Pathog. 2014 Mar 20;10(3):e1004010

pubmed: 24651464

J Virol. 2003 Aug;77(15):8227-36

pubmed: 12857891

Proc Natl Acad Sci U S A. 2015 Mar 10;112(10):E1126-34

pubmed: 25713386

Front Immunol. 2019 Feb 13;10:233

pubmed: 30815001

Clin Infect Dis. 2005 Aug 1;41(3):361-72

pubmed: 16007534

J Acquir Immune Defic Syndr. 2006 Aug 1;42(4):426-34

pubmed: 16810109

Cell. 2015 Feb 26;160(5):990-1001

pubmed: 25723172

Clin Infect Dis. 2018 Aug 31;67(6):927-933

pubmed: 29509894

PLoS One. 2009 Oct 30;4(10):e7658

pubmed: 19876401

Proc Natl Acad Sci U S A. 2013 Aug 13;110(33):13588-93

pubmed: 23898208

Cell. 2005 Jul 29;122(2):169-82

pubmed: 16051143

HIV Clin Trials. 2013 Mar-Apr;14(2):61-7

pubmed: 23611826

J Virol. 2006 Jul;80(13):6441-57

pubmed: 16775332

Clin Infect Dis. 2009 Feb 1;48(3):350-61

pubmed: 19123865

AIDS Res Hum Retroviruses. 2015 Jan;31(1):71-7

pubmed: 25092266

Proc Natl Acad Sci U S A. 2001 Feb 13;98(4):1781-6

pubmed: 11172028

J Gen Virol. 1997 Aug;78 ( Pt 8):1913-8

pubmed: 9266987

J Immunol. 2009 Mar 1;182(5):2888-97

pubmed: 19234184

J Infect Dis. 2010 Apr 1;201(7):1045-53

pubmed: 20170371

J Antimicrob Chemother. 2012 Jan;67(1):213-7

pubmed: 21987242

PLoS One. 2010 Nov 11;5(11):e13540

pubmed: 21085635

PLoS Pathog. 2020 Aug 25;16(8):e1008791

pubmed: 32841299

PLoS One. 2012;7(11):e48781

pubmed: 23152803

Retrovirology. 2014 Jun 24;11:49

pubmed: 24961156

AIDS. 2002 Oct 18;16(15):2035-41

pubmed: 12370502

Nat Med. 1998 Feb;4(2):208-14

pubmed: 9461195

Proc Natl Acad Sci U S A. 2007 Apr 17;104(16):6776-81

pubmed: 17428922

J Infect Dis. 2003 May 15;187(10):1534-43

pubmed: 12721933

J Clin Virol. 2001 Apr;21(1):81-9

pubmed: 11255101

J Infect Dis. 2005 Apr 15;191(8):1321-4

pubmed: 15776379

AIDS. 2003 Sep 5;17(13):1907-15

pubmed: 12960823

AIDS. 2016 Jan;30(2):327-30

pubmed: 26186129

Lancet. 2007 Aug 4;370(9585):407-13

pubmed: 17659333

J Clin Immunol. 2006 Jan;26(1):40-54

pubmed: 16418802